Found: 10
Select item for more details and to access through your institution.
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study).
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 509, doi. 10.1007/s40259-022-00543-9
- By:
- Publication type:
- Article
Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 521, doi. 10.1007/s40259-022-00542-w
- By:
- Publication type:
- Article
Pharmacists' Perspectives of Biosimilars: A Systematic Review.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 489, doi. 10.1007/s40259-022-00541-x
- By:
- Publication type:
- Article
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 537, doi. 10.1007/s40259-022-00540-y
- By:
- Publication type:
- Article
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 437, doi. 10.1007/s40259-022-00539-5
- By:
- Publication type:
- Article
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 431, doi. 10.1007/s40259-022-00538-6
- By:
- Publication type:
- Article
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 459, doi. 10.1007/s40259-022-00537-7
- By:
- Publication type:
- Article
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 443, doi. 10.1007/s40259-022-00536-8
- By:
- Publication type:
- Article
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
- Published in:
- BioDrugs, 2022, v. 36, n. 4, p. 473, doi. 10.1007/s40259-022-00527-9
- By:
- Publication type:
- Article